CHARLOTTE, N.C. / Apr 10, 2025 / Business Wire / Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 third quarter on Tuesday, May 6, 2025, at approximately 6:30 a.m. ET. The company will also host a conference call at 8:00 a.m. ET to discuss its financial results.
The live webcast and replay will be available in the Investors section of the company’s website at Events & Presentations. The webcast should be accessed 10 minutes prior to the conference call start time. The replay of the event will be available for one year following the conclusion of the live broadcast.
For those parties who do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and asking to join the Premier, Inc. call:
Domestic participant dial-in number (toll-free): | (833) 953-2438 |
International participant dial-in number: | (412) 317-5767 |
About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers, payers and policymakers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, consulting and other services in service of our mission to improve the health of communities. Please visit Premier’s news and investor sites on www.premierinc.com, as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.
Last Trade: | US$21.99 |
Daily Change: | 0.26 1.20 |
Daily Volume: | 2,646,604 |
Market Cap: | US$2.110B |
June 30, 2025 May 13, 2025 February 04, 2025 December 03, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load